Tobramycin – Injection products
Recognized Interpretive Criteria
FDA Identified Interpretive Criteria
|
Minimum Inhibitory |
Disk Diffusion |
||||
---|---|---|---|---|---|---|
Pathogen |
S |
I |
R |
S |
I |
R |
Enterobacterales |
≤ 4 |
8 |
≥ 16 |
≥ 15 |
13-14 |
≤ 12 |
Pseudomonas aeruginosa |
≤ 4 |
8 |
≥ 16 |
≥ 15 |
13-14 |
≤ 12 |
Staphylococcus aureus |
≤ 4 |
8 |
≥ 16 |
≥ 15 |
13-14 |
≤ 12 |
S = Susceptible; I = Intermediate; R = Resistant
Exceptions to the recognized standard of CLSI M100
For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:
Acinetobacter spp.
Other Non-Enterobacterales